Profile: Altimmune Inc (ALT.OQ)
18 Apr 2019
Altimmune, Inc., formerly Pharmathene, Inc., incorporated on April 25, 2005, is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies, RespirVec and Densigen. Its candidates include NasoVAX, HepTcell, NasoShield and Oncosyn.
NasoVAX is an intranasally administered recombinant influenza vaccine, which uses an adenovector to achieve expression of the influenza antigen in the target cell, thereby potentially stimulating a broader and more rapid immune response than traditional influenza vaccines. The Company has completed Phase I clinical trials of NasoVAX.
HepTcell is being tested as an immunotherapy for patients chronically infected with the hepatitis B virus (HBV). HepTcell is in Phase I clinical testing.
NasoShield is an intranasal, single-dose anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. NasoShield is in pre-clinical stage.
Oncosyn is being developed as a cancer immunotherapeutic product candidate. Oncosyn targets multiple tumor antigens simultaneous to prevent tumor escape. Oncosyn is in pre-clinical stage.
910 Clopper Rd Ste 201S
GAITHERSBURG MD 20878-1361